Global Multiple Myeloma Market to Reach US$ 36.57 Billion by 2034 Driven by Advancements in Targeted Therapies

Global Multiple Myeloma Market Analysis

The global multiple myeloma market was valued at approximately US$ 21.78 billion in 2024 and is projected to reach nearly US$ 40.41 billion by 2033, expanding at a CAGR of 7.11% during the forecast period from 2025 to 2033. Market growth is being driven by the increasing incidence of multiple myeloma worldwide, rising adoption of targeted therapies, and continuous advancements in immunotherapy-based treatment approaches. Growing investments in oncology research, improvements in diagnostic technologies, and expanding access to specialized cancer care are further supporting market expansion. In addition, increasing clinical development activities focused on novel biologics, CAR-T cell therapies, and personalized treatment strategies are contributing to the long-term growth potential of the multiple myeloma market.

Multiple Myeloma Market Outlook

Multiple myeloma is a hematological cancer that develops in plasma cells, a specialized type of white blood cell located in the bone marrow. Under normal conditions, plasma cells help protect the body from infections by producing antibodies that support the immune system. In multiple myeloma, abnormal plasma cells multiply uncontrollably and accumulate within the bone marrow, interfering with the production of healthy blood cells. This abnormal cell growth can lead to complications such as weakened bones, anemia, kidney dysfunction, immune suppression, and increased vulnerability to infections.

Although multiple myeloma is considered less common compared with several other cancer types, its global prevalence continues to increase due to population aging and improvements in disease detection. The condition primarily affects older adults, particularly individuals over the age of 60 years. Advances in medical diagnostics—including blood-based biomarkers, molecular testing, imaging technologies, and genetic profiling—have significantly improved early diagnosis and disease monitoring. Increased awareness among healthcare providers and patients, combined with expanding healthcare infrastructure and stronger research initiatives, is also contributing to improved disease management worldwide.

In recent years, major therapeutic advancements such as monoclonal antibodies, proteasome inhibitors, immunomodulatory drugs, and cellular therapies have transformed the treatment landscape for multiple myeloma. These innovations have helped improve survival rates, disease control, and overall quality of life for patients. Growing focus on precision medicine, combination therapies, and next-generation immunotherapies is expected to further reshape the market and create new opportunities for long-term treatment advancements globally.

Request Sample Report:https://www.renub.com/request-sample-page.php?gturl=multiple-myeloma-market-p.php

Multiple Myeloma: Absolute numbers, Incidence, Both sexes, in 2022

* Asia: 73,870 cases (39.3%)

* Europe: 50,092 cases (26.7%)

* Northern America: 37,050 cases (19.7%)

* Latin America & Caribbean (LAC): 15,194 cases (8.1%)

* Africa: 8,978 cases (4.8%)

* Oceania: 2,768 cases (1.5%)

* Total Global Incidence of Multiple Myeloma (Both Sexes, 2022): 187,952 cases

* By 2045, the number of newly diagnosed MM cases is expected to increase by more than 71% (or approximately to 321 000 cases per year) based solely on population growth and aging. Concurrently, the number of deaths from MM is expected to increase by approximately 79%, from 121 000 in 2022 to 218 000 in 2045.

Recent Developments in the Multiple Myeloma Market

* In September 2025, Lupin received U.S. FDA approval for its generic Lenalidomide Capsules (2.5 mg to 25 mg) for the treatment of multiple myeloma and selected myelodysplastic syndromes (MDS). The product is bioequivalent to Revlimid and will be manufactured at the company’s Pithampur production facility in India.

* In August 2025, Regeneron Pharmaceuticals highlighted the expanding clinical importance of Libtayo as a leading therapy for advanced cutaneous squamous cell carcinoma (CSCC), while also advancing ongoing development programs in melanoma and multiple myeloma treatment.

* In May 2025, GSK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of Blenrep for adults with relapsed or refractory multiple myeloma. The recommendation covered its use in combination with bortezomib and dexamethasone (BVd), as well as pomalidomide and dexamethasone (BPd), for patients previously treated with at least one therapy line.

* In May 2025, Johnson & Johnson announced that the FDA’s Oncologic Drugs Advisory Committee voted 6–2 in support of the benefit-risk profile of DARZALEX FASPRO for patients with high-risk smoldering multiple myeloma (HR-SMM). The supplemental FDA application for this indication had been submitted in November 2024.

* In April 2025, Halozyme announced that the European Commission approved an expanded indication for subcutaneous DARZALEX co-formulated with ENHANZE. The updated approval covers use in newly diagnosed multiple myeloma patients in combination with bortezomib, lenalidomide, and dexamethasone.

Growth Driver of the Multiple Myeloma Market

Rising Prevalence of Multiple Myeloma and Expanding Elderly Population

One of the primary factors driving growth in the multiple myeloma market is the increasing number of diagnosed cases worldwide. Multiple myeloma primarily affects older adults, and the steady rise in global life expectancy is significantly expanding the patient population. As aging populations continue to grow across both developed and emerging economies, the prevalence of age-related hematological cancers such as multiple myeloma is also increasing. Improved healthcare accessibility, greater awareness of blood cancers, and wider availability of diagnostic services are enabling earlier and more frequent disease detection. This has contributed to a growing demand for long-term treatment and disease management solutions. Since multiple myeloma is a chronic and relapsing condition that often requires continuous therapy and ongoing monitoring, the expanding patient base is directly supporting sustained market growth. In addition, improvements in supportive care and treatment outcomes are helping patients live longer, further increasing the need for advanced therapeutic options and comprehensive disease management strategies.

Advancements in Targeted Therapies and Immunotherapy Treatments

Rapid advancements in targeted therapies and immunotherapy approaches have significantly transformed the treatment landscape for multiple myeloma and are serving as major drivers of market expansion. Innovative drug classes including monoclonal antibodies, proteasome inhibitors, bispecific antibodies, CAR-T cell therapies, and immunomodulatory agents have demonstrated improved clinical efficacy and better safety profiles compared with traditional chemotherapy-based treatments. These advanced therapies specifically target cancer cells or enhance the body’s immune response against malignant plasma cells, resulting in improved survival outcomes and enhanced quality of life for patients. The increasing use of combination treatment regimens has further strengthened therapeutic effectiveness by improving disease control and reducing relapse rates. Pharmaceutical companies continue to invest heavily in research and development activities aimed at introducing next-generation therapies with greater precision and reduced toxicity. Continuous innovation, strong clinical pipelines, and increasing regulatory approvals for novel treatments are accelerating the adoption of advanced multiple myeloma therapies across global healthcare markets.

Growing Oncology Research Activities and Enhanced Diagnostic Technologies

Increasing investments in oncology research and ongoing improvements in diagnostic technologies are playing a critical role in the growth of the multiple myeloma market. Governments, biotechnology companies, pharmaceutical manufacturers, and academic research institutions are expanding funding for cancer research programs focused on developing innovative therapies and improving patient outcomes. At the same time, advancements in diagnostic capabilities—including molecular diagnostics, genetic profiling, biomarker analysis, next-generation sequencing, and advanced imaging technologies—are enabling earlier and more accurate detection of multiple myeloma. Early diagnosis allows healthcare providers to initiate treatment sooner, helping improve disease management and long-term survival rates. Expanding access to specialized cancer centers, laboratory testing facilities, and advanced diagnostic infrastructure is also supporting broader identification of multiple myeloma cases worldwide. In addition, growing awareness among physicians and patients regarding the benefits of routine screening and personalized medicine is contributing to increased treatment adoption. These developments collectively continue to strengthen market growth and accelerate innovation within the global multiple myeloma treatment landscape.

Segment Analysis

Multiple Myeloma Chemotherapy Market

The multiple myeloma chemotherapy market continues to play an important role in the treatment and management of the disease, particularly during initial therapy and in combination treatment strategies. Chemotherapy drugs are widely used to destroy rapidly dividing cancerous plasma cells and help reduce tumor burden in patients with multiple myeloma. Although targeted therapies and immunotherapies have transformed treatment approaches in recent years, chemotherapy remains a widely utilized option, especially in healthcare systems where access to advanced biologic therapies may be limited. Chemotherapy is frequently administered alongside corticosteroids or as part of conditioning regimens prior to stem cell transplantation to improve therapeutic outcomes. Established clinical protocols and broad treatment applicability continue to support the use of chemotherapy in multiple myeloma management. In addition, advancements in supportive care, dosing strategies, and combination regimens have improved treatment tolerability and reduced adverse effects. As part of integrated multi-drug treatment approaches, chemotherapy remains a critical component of comprehensive multiple myeloma care worldwide.

Multiple Myeloma Proteasome Inhibitors Market

The multiple myeloma proteasome inhibitors market is experiencing strong growth due to the high clinical effectiveness of this drug class in controlling disease progression and improving patient survival outcomes. Proteasome inhibitors work by disrupting protein degradation pathways within cancer cells, leading to cellular stress and apoptosis of malignant plasma cells. These therapies have become a cornerstone of modern multiple myeloma treatment and are commonly used in combination with immunomodulatory drugs, monoclonal antibodies, and corticosteroids to enhance therapeutic efficacy. Proteasome inhibitors are widely prescribed for both newly diagnosed patients and individuals with relapsed or refractory disease because of their proven ability to improve disease control and extend progression-free survival. Ongoing pharmaceutical innovation continues to drive the development of newer formulations with enhanced efficacy, improved administration methods, and reduced side effects. Increasing adoption of combination treatment protocols and expanding regulatory approvals for advanced proteasome inhibitor therapies are further supporting market growth across global oncology and hematology care settings.

Active Multiple Myeloma Market

The active multiple myeloma market focuses on patients with symptomatic disease who require immediate and intensive therapeutic intervention. Active multiple myeloma is typically characterized by clinical complications such as bone lesions, anemia, kidney impairment, hypercalcemia, and organ dysfunction caused by malignant plasma cell proliferation. Managing active disease requires aggressive and sustained treatment strategies aimed at controlling progression, reducing complications, and improving long-term patient outcomes. Rising prevalence of symptomatic multiple myeloma and improvements in diagnostic technologies are contributing to increased identification of patients requiring active treatment. The availability of advanced therapeutic options—including targeted therapies, immunotherapies, proteasome inhibitors, and combination drug regimens—has significantly improved disease management and survival rates for patients with active multiple myeloma. Healthcare providers are increasingly adopting personalized treatment approaches based on disease stage, genetic factors, and patient condition to optimize clinical outcomes. Continued innovation in therapeutic development and expanding access to specialized oncology care are expected to support ongoing market growth.

Multiple Myeloma Hospitals Market

Hospitals remain the primary centers for the diagnosis, treatment, and long-term management of multiple myeloma due to the complexity of the disease and the need for specialized multidisciplinary care. Tertiary care hospitals, oncology centers, and specialized cancer institutions provide comprehensive services including diagnostic testing, chemotherapy, immunotherapy, stem cell transplantation, supportive care, and disease monitoring. Hospitals play a crucial role in delivering advanced treatment protocols and managing complications associated with multiple myeloma, particularly for patients requiring intensive therapies or inpatient care. The growing number of cancer treatment facilities and expanding oncology infrastructure worldwide are contributing to increased demand for hospital-based multiple myeloma services. In addition, hospitals provide access to advanced diagnostic technologies, clinical trials, personalized medicine programs, and highly specialized hematology teams, strengthening their importance within the treatment ecosystem. Rising investments in cancer care infrastructure and improved healthcare accessibility are further supporting growth within the multiple myeloma hospitals market globally.

Ask Analyst for Customization in Report:https://www.renub.com/request-customization-page.php?gturl=multiple-myeloma-market-p.php

Country Analysis

United States Multiple Myeloma Market

The United States represents the largest multiple myeloma market globally, supported by a high disease prevalence, advanced healthcare infrastructure, and rapid adoption of innovative oncology therapies. The country leads in the use of targeted treatments, immunotherapies, CAR-T cell therapies, monoclonal antibodies, and combination drug regimens that have significantly improved patient survival and quality of life. Strong investments in cancer research and continuous expansion of clinical development pipelines are driving the introduction of next-generation therapies and personalized treatment approaches. Advanced diagnostic technologies, including molecular profiling and genetic testing, enable earlier disease detection and more precise treatment planning. In addition, the widespread presence of specialized cancer centers and hematology clinics supports comprehensive disease management. Favorable reimbursement frameworks and the strong presence of leading pharmaceutical and biotechnology companies further accelerate access to innovative therapies. As multiple myeloma increasingly becomes a long-term manageable condition, demand for ongoing treatment, monitoring, and supportive care continues to drive steady market growth across the United States.

United Kingdom Multiple Myeloma Market

The United Kingdom multiple myeloma market is experiencing gradual expansion due to growing awareness of blood cancers, improvements in early diagnosis, and increasing adoption of advanced treatment therapies. The use of targeted therapies, immunomodulatory drugs, monoclonal antibodies, and combination treatment regimens has significantly improved patient outcomes and disease management across the country. The UK healthcare system’s strong emphasis on evidence-based oncology care and standardized treatment pathways supports consistent adoption of modern therapies for multiple myeloma patients. Specialized cancer centers, tertiary hospitals, and hematology clinics continue to play a central role in diagnosis, treatment, and long-term patient monitoring. In addition, participation in clinical trials and ongoing oncology research activities are contributing to the introduction of innovative treatment options within the country. Improved survival rates and longer treatment durations are also increasing demand for maintenance therapies and supportive care services. These factors collectively continue to strengthen growth in the United Kingdom multiple myeloma market.

India Multiple Myeloma Market

The India multiple myeloma market is growing steadily due to increasing cancer awareness, expanding diagnostic capabilities, and improving access to oncology treatment services. Rising incidence of blood cancers, a large aging population, and growing healthcare utilization are contributing to increased demand for multiple myeloma therapies across the country. Advances in diagnostic infrastructure, including improved laboratory testing and imaging technologies, are supporting earlier disease identification and treatment initiation. Although access to advanced therapies remains more concentrated in urban healthcare centers, major hospitals and specialty oncology institutions are gradually expanding availability across broader regions. Affordable treatment options and the increasing availability of generic oncology medications are also helping improve patient access to therapy. The rapid growth of private healthcare providers and specialized cancer treatment facilities is further strengthening the country’s oncology care ecosystem. Continued healthcare infrastructure development, increasing awareness programs, and rising investments in cancer care are expected to support long-term expansion of the India multiple myeloma market.

Saudi Arabia Multiple Myeloma Market

The Saudi Arabia multiple myeloma market is gradually emerging as the country continues investing in advanced oncology infrastructure and specialized cancer care services. Increasing diagnosis rates, improving healthcare accessibility, and growing availability of tertiary care hospitals are contributing to rising demand for multiple myeloma treatments. Healthcare providers across major medical centers are increasingly adopting modern treatment approaches, including targeted therapies, immunotherapies, and advanced supportive care protocols for hematological cancers. Government initiatives focused on improving cancer screening, early diagnosis, and access to specialized oncology treatment are further supporting market development. Expansion of healthcare infrastructure under national healthcare transformation programs is also enhancing the availability of advanced diagnostic technologies and cancer treatment services throughout the Kingdom. In addition, growing awareness regarding blood cancers and the importance of early intervention is encouraging greater utilization of oncology care services. As Saudi Arabia continues modernizing its healthcare sector and strengthening oncology capabilities, the multiple myeloma market is expected to witness steady growth in the coming years.

Market Segments

Drugs Types

·      Chemotherapy

·      Protease Inhibitors

·      Monoclonal Antibody

·      Others

Disease Types

·      Active multiple myeloma

·      Smoldering multiple myeloma

End User

·      Hospitals

·      Clinics

·      Others

Regional Insights:

North America

·      United States

·      Canada

Europe

·      France

·      Germany

·      Italy

·      Spain

·      United Kingdom

·      Belgium

·      Netherlands

·      Turkey

Asia Pacific

·      China

·      Japan

·      India

·      Australia

·      South Korea

·      Thailand

·      Malaysia

·      Indonesia

·      New Zealand

Latin America

·      Brazil

·      Mexico

·      Argentina

Middle East & Africa

·      South Africa

·      Saudi Arabia

·      UAE

All the Key players have been covered from 4 Viewpoints:

·      Overviews

·      Key Person

·      Recent Developments

·      Product Portfolio    

·      Revenue

Competitive Landscape and Key Players

·      Novartis AG

·      Abbvie Inc.

·      Sanofi

·      Johnson and Johnson

·      Baxter International Inc.

·      Pfizer Inc.

·      Takeda Pharmaceutical Company Ltd

·      Bristol-Myers Squibb Company

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.        

Contact Us:

Company Name: Renub Research

Contact Person: Rajat Gupta

Phone No: (D) +91-120-421-9822 (IND)

Website: https://www.renub.com/

Email: rajat@renub.com